Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid.

Schwieler L, Trepci A, Krzyzanowski S, Hermansson S, Granqvist M, Piehl F, Venckunas T, Brazaitis M, Kamandulis S, Lindqvist D, Jones AD, Erhardt S, Brundin L.

Bioanalysis. 2020 Mar 25. doi: 10.4155/bio-2019-0303. [Epub ahead of print]

2.

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T; MSBase study group.

Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.

PMID:
32199096
3.

Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis.

Ouellette R, Mangeat G, Polyak I, Warntjes M, Forslin Y, Bergendal Å, Plattén M, Uppman M, Treaba CA, Cohen-Adad J, Piehl F, Kristoffersen Wiberg M, Fredrikson S, Mainero C, Granberg T.

Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705. [Epub ahead of print]

PMID:
32057118
4.

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.

Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701. [Epub ahead of print]

PMID:
32056253
5.

Blood neurofilament light levels segregate treatment effects in multiple sclerosis.

Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F.

Neurology. 2020 Mar 17;94(11):e1201-e1212. doi: 10.1212/WNL.0000000000009097. Epub 2020 Feb 11.

PMID:
32047070
6.

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels.

Manouchehrinia A, Piehl F, Hillert J, Kuhle J, Alfredsson L, Olsson T, Kockum I.

Ann Clin Transl Neurol. 2020 Jan;7(1):139-143. doi: 10.1002/acn3.50972. Epub 2020 Jan 1.

7.

MRI-Based Manual versus Automated Corpus Callosum Volumetric Measurements in Multiple Sclerosis.

Platten M, Martola J, Fink K, Ouellette R, Piehl F, Granberg T.

J Neuroimaging. 2020 Mar;30(2):198-204. doi: 10.1111/jon.12676. Epub 2019 Nov 20.

PMID:
31750599
8.

Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.

Juto A, Fink K, Al Nimer F, Piehl F.

Mult Scler Relat Disord. 2020 Jan;37:101468. doi: 10.1016/j.msard.2019.101468. Epub 2019 Oct 24.

PMID:
31683231
9.

Different epigenetic clocks reflect distinct pathophysiological features of multiple sclerosis.

Theodoropoulou E, Alfredsson L, Piehl F, Marabita F, Jagodic M.

Epigenomics. 2019 Sep;11(12):1429-1439. doi: 10.2217/epi-2019-0102. Epub 2019 Oct 8.

10.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T.

JAMA Neurol. 2019 Oct 7. doi: 10.1001/jamaneurol.2019.3365. [Epub ahead of print]

PMID:
31589278
11.

Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis.

Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum I, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M.

Mult Scler Relat Disord. 2019 Nov;36:101414. doi: 10.1016/j.msard.2019.101414. Epub 2019 Sep 26.

PMID:
31574404
12.

Successful combined treatment with thymectomy, rituximab and tocilizumab for severe thymoma-associated multi autoimmune syndrome.

Sveinsson O, Piehl F, Aspegren O, Hietala MA.

J Neuroimmunol. 2019 Nov 15;336:577028. doi: 10.1016/j.jneuroim.2019.577028. Epub 2019 Aug 23.

PMID:
31472400
13.

Epilepsy in systemic lupus erythematosus: prevalence and risk factors.

Hopia L, Andersson M, Svenungsson E, Khademi M, Piehl F, Tomson T.

Eur J Neurol. 2020 Feb;27(2):297-307. doi: 10.1111/ene.14077. Epub 2019 Oct 8.

PMID:
31454130
14.

Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients.

Fernandes SJ, Morikawa H, Ewing E, Ruhrmann S, Joshi RN, Lagani V, Karathanasis N, Khademi M, Planell N, Schmidt A, Tsamardinos I, Olsson T, Piehl F, Kockum I, Jagodic M, Tegnér J, Gomez-Cabrero D.

Sci Rep. 2019 Aug 19;9(1):11996. doi: 10.1038/s41598-019-48493-7.

15.

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.

Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, Sundström P, Svenningsson A, Vrethem M, Frisell T, Piehl F.

Mult Scler. 2019 Aug 8:1352458519866600. doi: 10.1177/1352458519866600. [Epub ahead of print]

PMID:
31392923
16.

Incidence of osmotic demyelination syndrome in Sweden: A nationwide study.

Aegisdottir H, Cooray C, Wirdefeldt K, Piehl F, Sveinsson O.

Acta Neurol Scand. 2019 Nov;140(5):342-349. doi: 10.1111/ane.13150. Epub 2019 Aug 19.

PMID:
31343728
17.

GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis.

Galli E, Hartmann FJ, Schreiner B, Ingelfinger F, Arvaniti E, Diebold M, Mrdjen D, van der Meer F, Krieg C, Nimer FA, Sanderson N, Stadelmann C, Khademi M, Piehl F, Claassen M, Derfuss T, Olsson T, Becher B.

Nat Med. 2019 Aug;25(8):1290-1300. doi: 10.1038/s41591-019-0521-4. Epub 2019 Jul 22.

18.

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.

Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, Checa A, Badam TVS, Huang J, Gomez-Cabrero D, Gustafsson M, Al Nimer F, Wheelock CE, Kockum I, Olsson T, Jagodic M, Piehl F.

Nat Commun. 2019 Jul 12;10(1):3081. doi: 10.1038/s41467-019-11139-3.

19.

Rituximab treatment for multiple sclerosis.

Ineichen BV, Moridi T, Granberg T, Piehl F.

Mult Scler. 2020 Feb;26(2):137-152. doi: 10.1177/1352458519858604. Epub 2019 Jun 25.

PMID:
31237800
20.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
21.

Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis.

Kular L, Needhamsen M, Adzemovic MZ, Kramarova T, Gomez-Cabrero D, Ewing E, Piket E, Tegnér J, Beck S, Piehl F, Brundin L, Jagodic M.

Clin Epigenetics. 2019 May 30;11(1):86. doi: 10.1186/s13148-019-0678-1.

22.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
23.

A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury.

Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nyström H, Svensson M, Bellander BM, Piehl F, Nelson DW.

J Neurotrauma. 2019 Oct 15;36(20):2850-2862. doi: 10.1089/neu.2019.6375. Epub 2019 Jun 19.

24.

Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression.

Ewing E, Kular L, Fernandes SJ, Karathanasis N, Lagani V, Ruhrmann S, Tsamardinos I, Tegner J, Piehl F, Gomez-Cabrero D, Jagodic M.

EBioMedicine. 2019 May;43:411-423. doi: 10.1016/j.ebiom.2019.04.042. Epub 2019 Apr 30.

25.

Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.

Minta K, Cullen NC, Nimer FA, Thelin EP, Piehl F, Clarin M, Tullberg M, Jeppsson A, Portelius E, Zetterberg H, Blennow K, Andreasson U.

Clin Chem Lab Med. 2019 Sep 25;57(10):1565-1573. doi: 10.1515/cclm-2019-0034.

PMID:
30980710
26.

Morvan's syndrome treated successfully with rituximab and lacosamide.

Sveinsson O, Al Nimer F, Piehl F.

BMJ Case Rep. 2019 Feb 13;12(2). pii: e226832. doi: 10.1136/bcr-2018-226832.

PMID:
30765442
27.

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J.

Eur J Neurol. 2019 Aug;26(8):1060-1067. doi: 10.1111/ene.13936. Epub 2019 Mar 12.

PMID:
30762259
28.

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group.

Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.

29.

Increased peripheral levels of TARC/CCL17 in first episode psychosis patients.

Malmqvist A, Schwieler L, Orhan F, Fatouros-Bergman H, Bauer M, Flyckt L, Cervenka S, Engberg G, Piehl F; Karolinska Schizophrenia Project (KaSP) consortium, Erhardt S.

Schizophr Res. 2019 Aug;210:221-227. doi: 10.1016/j.schres.2018.12.033. Epub 2019 Jan 3.

PMID:
30612841
30.

B cell alterations during BAFF inhibition with belimumab in SLE.

Ramsköld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikeš J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmström V.

EBioMedicine. 2019 Feb;40:517-527. doi: 10.1016/j.ebiom.2018.12.035. Epub 2018 Dec 26.

31.

Author Correction: Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 22;4(1):49. doi: 10.1038/s41572-018-0050-3.

PMID:
30467372
32.

Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.

PMID:
30410033
33.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1.

34.

The association between multiple sclerosis and pain medications.

Burkill S, Montgomery S, Kockum I, Piehl F, Strid P, Hillert J, Alfredsson L, Olsson T, Bahmanyar S.

Pain. 2019 Feb;160(2):424-432. doi: 10.1097/j.pain.0000000000001429. Erratum in: Pain. 2019 Apr;160(4):986.

PMID:
30376533
35.

miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome.

Johansson A, Nyberg WA, Sjöstrand M, Moruzzi N, Bergman P, Khademi M, Andersson M, Piehl F, Berggren PO, Covacu R, Jagodic M, Espinosa A.

Eur J Immunol. 2019 Feb;49(2):313-322. doi: 10.1002/eji.201747416. Epub 2018 Oct 22.

36.

Identification of MS-specific serum miRNAs in an international multicenter study.

Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep.

37.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

38.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
39.

Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis.

Orhan F, Schwieler L, Fatouros-Bergman H, Malmqvist A, Cervenka S, Collste K, Flyckt L, Farde L, Sellgren CM, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Engberg G, Erhardt S.

Acta Psychiatr Scand. 2018 Nov;138(5):432-440. doi: 10.1111/acps.12944. Epub 2018 Aug 21.

PMID:
30132802
40.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

41.

Polygenic link between blood lipids and amyotrophic lateral sclerosis.

Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F.

Neurobiol Aging. 2018 Jul;67:202.e1-202.e6. doi: 10.1016/j.neurobiolaging.2018.03.022. Epub 2018 Mar 27.

PMID:
29685649
42.

Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients.

Checa A, Malmqvist A, Flyckt L, Schwieler L, Samuelsson M, Skogh E, Cervenka S, Dahl ML, Piehl F; Karolinska Schizophrenia Project (KaSP) Consortium, Erhardt S, Wheelock CE.

Schizophr Res. 2018 Sep;199:438-441. doi: 10.1016/j.schres.2018.03.029. Epub 2018 Apr 4. No abstract available.

PMID:
29627172
43.

Susceptibility to Oxidative Stress Is Determined by Genetic Background in Neuronal Cell Cultures.

Günther M, Al Nimer F, Piehl F, Risling M, Mathiesen T.

eNeuro. 2018 Mar 19;5(2). pii: ENEURO.0335-17.2018. doi: 10.1523/ENEURO.0335-17.2018. eCollection 2018 Mar-Apr.

44.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.

Piehl F, Hillert J.

Mult Scler. 2018 Aug;24(9):1157-1159. doi: 10.1177/1352458518757930. Epub 2018 Feb 22. No abstract available.

PMID:
29468952
45.

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.

Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 May;74(5):663-670. doi: 10.1007/s00228-018-2429-1. Epub 2018 Feb 10.

46.

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis.

Birkeldh U, Manouchehrinia A, Hietala MA, Hillert J, Olsson T, Piehl F, Kockum IS, Brundin L, Zahavi O, Wahlberg-Ramsay M, Brautaset R, Nilsson M.

Front Neurol. 2017 Dec 13;8:675. doi: 10.3389/fneur.2017.00675. eCollection 2017.

47.

Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients.

James T, Lindén M, Morikawa H, Fernandes SJ, Ruhrmann S, Huss M, Brandi M, Piehl F, Jagodic M, Tegnér J, Khademi M, Olsson T, Gomez-Cabrero D, Kockum I.

Hum Mol Genet. 2018 Mar 1;27(5):912-928. doi: 10.1093/hmg/ddy001.

PMID:
29325110
48.

Depression and fatigue in multiple sclerosis: Relation to exposure to violence and cerebrospinal fluid immunomarkers.

Brenner P, Granqvist M, Königsson J, Al Nimer F, Piehl F, Jokinen J.

Psychoneuroendocrinology. 2018 Mar;89:53-58. doi: 10.1016/j.psyneuen.2018.01.002. Epub 2018 Jan 4.

PMID:
29324301
49.

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F.

JAMA Neurol. 2018 Mar 1;75(3):320-327. doi: 10.1001/jamaneurol.2017.4011.

50.

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study.

Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2018 Feb;74(2):219-226. doi: 10.1007/s00228-017-2366-4. Epub 2017 Nov 11.

Supplemental Content

Support Center